The FDA granted priority-review designation to Eli Lilly & Co.'s biologics license application for ramucirumab, or IMC-1121B, for treatment of patients with advanced gastric cancer whose disease progressed after initial chemotherapy. The drug is also under regulatory review in Europe.
FDA to expedite review of Lilly's gastric cancer drug
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management